Format

Send to

Choose Destination
Cell Rep. 2014 Mar 13;6(5):868-77. doi: 10.1016/j.celrep.2014.02.004. Epub 2014 Feb 27.

Histone demethylase RBP2 is critical for breast cancer progression and metastasis.

Author information

1
Department of Pathology, Yale School of Medicine, New Haven, CT 06520, USA.
2
Cancer and Developmental Cell Biology Division, Institute of Molecular and Cell Biology, 61 Biopolis Drive, Singapore 138673, Singapore.
3
Section of Comparative Medicine, Yale School of Medicine, New Haven, CT 06520, USA.
4
Department of Pathology, Yale School of Medicine, New Haven, CT 06520, USA. Electronic address: qin.yan@yale.edu.

Abstract

Metastasis is a major clinical challenge for cancer treatment. Emerging evidence suggests that aberrant epigenetic modifications contribute significantly to tumor formation and progression. However, the drivers and roles of such epigenetic changes in tumor metastasis are still poorly understood. Using bioinformatic analysis of human breast cancer gene-expression data sets, we identified histone demethylase RBP2 as a putative mediator of metastatic progression. By using both human breast cancer cells and genetically engineered mice, we demonstrated that RBP2 is critical for breast cancer metastasis to the lung in multiple in vivo models. Mechanistically, RBP2 promotes metastasis as a pleiotropic positive regulator of many metastasis genes, including TNC. In addition, RBP2 loss suppresses tumor formation in MMTV-neu transgenic mice. These results suggest that therapeutic targeting of RBP2 is a potential strategy for inhibition of tumor progression and metastasis.

PMID:
24582965
PMCID:
PMC4014129
DOI:
10.1016/j.celrep.2014.02.004
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center